These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8704239)

  • 1. Autotransplants in multiple myeloma: what have we learned?
    Vesole DH; Tricot G; Jagannath S; Desikan KR; Siegel D; Bracy D; Miller L; Cheson B; Crowley J; Barlogie B
    Blood; 1996 Aug; 88(3):838-47. PubMed ID: 8704239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total therapy with tandem transplants for newly diagnosed multiple myeloma.
    Barlogie B; Jagannath S; Desikan KR; Mattox S; Vesole D; Siegel D; Tricot G; Munshi N; Fassas A; Singhal S; Mehta J; Anaissie E; Dhodapkar D; Naucke S; Cromer J; Sawyer J; Epstein J; Spoon D; Ayers D; Cheson B; Crowley J
    Blood; 1999 Jan; 93(1):55-65. PubMed ID: 9864146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
    Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
    Bone Marrow Transplant; 1998 Jun; 21(11):1101-7. PubMed ID: 9645572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
    Badros A; Barlogie B; Siegel E; Roberts J; Langmaid C; Zangari M; Desikan R; Shaver MJ; Fassas A; McConnell S; Muwalla F; Barri Y; Anaissie E; Munshi N; Tricot G
    Br J Haematol; 2001 Sep; 114(4):822-9. PubMed ID: 11564069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.
    Vesole DH; Barlogie B; Jagannath S; Cheson B; Tricot G; Alexanian R; Crowley J
    Blood; 1994 Aug; 84(3):950-6. PubMed ID: 7913845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
    Desikan KR; Tricot G; Dhodapkar M; Fassas A; Siegel D; Vesole DH; Jagannath S; Singhal S; Mehta J; Spoon D; Anaissie E; Barlogie B; Munshi N
    Bone Marrow Transplant; 2000 Mar; 25(5):483-7. PubMed ID: 10713623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years.
    Badros A; Barlogie B; Siegel E; Morris C; Desikan R; Zangari M; Fassas A; Anaissie E; Munshi N; Tricot G
    Br J Haematol; 2001 Sep; 114(3):600-7. PubMed ID: 11552985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous stem cell transplantation for multiple myeloma: identification of prognostic factors.
    Kumar L; Cyriac SL; Tejomurtula TV; Bahl A; Biswas B; Sahoo RK; Mukherjee A; Sharma O
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):32-41. PubMed ID: 23085487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
    Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
    Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.
    Alegre A; Díaz-Mediavilla J; San-Miguel J; Martínez R; García Laraña J; Sureda A; Lahuerta JJ; Morales D; Bladé J; Caballero D; De la Rubia J; Escudero A; Díez-Martín JL; Hernández-Navarro F; Rifón J; Odriozola J; Brunet S; De la Serna J; Besalduch J; Vidal MJ; Solano C; Leon A; Sánchez JJ; Martínez-Chamorro C; Fernández-Rañada JM
    Bone Marrow Transplant; 1998 Jan; 21(2):133-40. PubMed ID: 9489629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell transplants for multiple myeloma.
    Tricot G; Jagannath S; Vesole DH; Bracy D; Desikan KR; Siegel D; Barlogie B
    Leuk Lymphoma; 1996 Jun; 22(1-2):25-36. PubMed ID: 8724525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
    Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early myeloablative therapy for multiple myeloma.
    Alexanian R; Dimopoulos MA; Hester J; Delasalle K; Champlin R
    Blood; 1994 Dec; 84(12):4278-82. PubMed ID: 7994043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
    Tricot G; Sawyer JR; Jagannath S; Desikan KR; Siegel D; Naucke S; Mattox S; Bracy D; Munshi N; Barlogie B
    J Clin Oncol; 1997 Jul; 15(7):2659-66. PubMed ID: 9215838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma.
    Goldschmidt H; Hegenbart U; Wallmeier M; Hohaus S; Engenhart R; Wannenmacher M; Haas R
    Ann Oncol; 1997 Mar; 8(3):243-6. PubMed ID: 9137792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
    Tricot G; Jagannath S; Vesole D; Nelson J; Tindle S; Miller L; Cheson B; Crowley J; Barlogie B
    Blood; 1995 Jan; 85(2):588-96. PubMed ID: 7529066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma.
    Abraham R; Chen C; Tsang R; Simpson D; Murray C; Davidson M; Meharchand J; Sutton DM; Crump RM; Keating A; Stewart AK
    Bone Marrow Transplant; 1999 Dec; 24(12):1291-7. PubMed ID: 10627637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
    Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.
    Hunter HM; Peggs K; Powles R; Rahemtulla A; Mahendra P; Cavenagh J; Littlewood T; Potter M; Hunter A; Pagliuca A; Williams CD; Cook G; Towlson K; Marks David I; Russell NH;
    Br J Haematol; 2005 Feb; 128(4):496-502. PubMed ID: 15686458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.